Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Liver Diseases

Free Subscription Articles published in Lancet Retrieve available abstracts of 20 articles: HTML format Text format

Single Articles

January 2019
1. BRAILLON A
   Laennec's cirrhosis.
   Lancet. 2019;393:131-132.
   PubMed     Text format    
   
   
   December 2018
2. WONG VWS, Adams LA
   Fibroblast growth factor 21 for non-alcoholic steatohepatitis.
   Lancet. 2018 Dec 13. pii: S0140-6736(18)32165.
   PubMed     Text format    
   
   
   
3. SANYAL A, Charles ED, Neuschwander-Tetri BA, Loomba R, et al
   Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
   Lancet. 2018 Dec 13. pii: S0140-6736(18)31785.
   PubMed     Text format     Abstract available
   
   
   November 2018
4. CARACENI P, Roncadori A, Bernardi M
   Questions in the design of ANSWER - Authors' reply.
   Lancet. 2018;392:1623-1624.
   PubMed     Text format    
   
   
   
5. ROWE IA, Parker R
   Questions in the design of ANSWER.
   Lancet. 2018;392:1623.
   PubMed     Text format    
   
   
   August 2018
6. MANNS MP, Burra P, Sargent J, Horton R, et al
   The Lancet-EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities.
   Lancet. 2018;392:621-622.
   PubMed     Text format    
   
   
   July 2018
7. BARNETT R
   Liver cirrhosis.
   Lancet. 2018;392:275.
   PubMed     Text format    
   
   
   May 2018
8. GARCIA-TSAO G
   Long-term albumin in cirrhosis: is it the ANSWER?
   Lancet. 2018 May 31. pii: S0140-6736(18)30948.
   PubMed     Text format    
   
   
   
9. CARACENI P, Riggio O, Angeli P, Alessandria C, et al
   Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
   Lancet. 2018 May 31. pii: S0140-6736(18)30840.
   PubMed     Text format     Abstract available
   
   
   March 2018
10. CHARLTON M
    FGF-19 agonism for NASH: a short study of a long disease.
    Lancet. 2018;391:1124-1126.
    PubMed     Text format    
    
    
    
11. REIG M, Bruix J
    Lenvatinib: can a non-inferiority trial change clinical practice?
    Lancet. 2018;391:1123-1124.
    PubMed     Text format    
    
    
    
12. HARRISON SA, Rinella ME, Abdelmalek MF, Trotter JF, et al
    NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2018 Mar 5. pii: S0140-6736(18)30474.
    PubMed     Text format     Abstract available
    
    
    February 2018
13. KUDO M, Finn RS, Qin S, Han KH, et al
    Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Lancet. 2018 Feb 9. pii: S0140-6736(18)30207.
    PubMed     Text format     Abstract available
    
    
    January 2018
14. PATTEN DA, Shetty S
    Chronic liver disease: scavenger hunt for novel therapies.
    Lancet. 2018;391:104-105.
    PubMed     Text format    
    
    
    
15. FORNER A, Reig M, Bruix J
    Hepatocellular carcinoma.
    Lancet. 2018 Jan 4. pii: S0140-6736(18)30010.
    PubMed     Text format     Abstract available
    
    
    August 2017
16. SCHACHTER J, Ribas A, Long GV, Arance A, et al
    Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31601.
    PubMed     Text format     Abstract available
    
    
    April 2017
17. WORNS MA, Galle PR
    Immune oncology in hepatocellular carcinoma-hype and hope.
    Lancet. 2017 Apr 20. pii: S0140-6736(17)31044.
    PubMed     Text format    
    
    
    
18. EL-KHOUEIRY AB, Sangro B, Yau T, Crocenzi TS, et al
    Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    Lancet. 2017 Apr 20. pii: S0140-6736(17)31046.
    PubMed     Text format     Abstract available
    
    
    February 2017
19. HEGADE VS, Kendrick SF, Dobbins RL, Miller SR, et al
    Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Lancet. 2017 Feb 7. pii: S0140-6736(17)30319.
    PubMed     Text format     Abstract available
    
    
    November 2016
20. KIRBY T
    Profile: The Kirby Institute celebrates 30 years.
    Lancet. 2016;388:2466.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: